CX3CR1 and rheumatoid arthritis: Furthermore, the expression of synovial fibroblast CX3CL1 and CX3CR1 expressed by CD8+ T cells has been shown to positively correlate with RA severity (125) and monoclonal antibody treatment targeting CX3CL1 has shown to be successful in early phase clinical trials in RA (126).